0001415889-25-021663.txt : 20250813 0001415889-25-021663.hdr.sgml : 20250813 20250813165329 ACCESSION NUMBER: 0001415889-25-021663 CONFORMED SUBMISSION TYPE: SCHEDULE 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250813 DATE AS OF CHANGE: 20250813 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IN8BIO, INC. CENTRAL INDEX KEY: 0001740279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 825462585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92777 FILM NUMBER: 251212523 BUSINESS ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: (646) 600-6438 MAIL ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: Incysus Therapeutics, Inc. DATE OF NAME CHANGE: 20180510 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Ho William Tai-Wei CENTRAL INDEX KEY: 0001830914 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SCHEDULE 13G/A MAIL ADDRESS: STREET 1: C/O IN8BIO, INC. STREET 2: 79 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10016 SCHEDULE 13G/A 1 primary_doc.xml SCHEDULE 13G/A 0001415889-25-004123 0001830914 XXXXXXXX LIVE 3 Common Stock, $0.0001 Par Value Per Share 06/30/2025 0001740279 IN8BIO, INC. 45674E208 EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 Rule 13d-1(d) William Tai-Wei Ho X1 142709.00 8514.00 142709.00 4866.00 151223.00 3.7 IN IN8BIO, INC. EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118. This Schedule 13G is filed by William Tai-Wei Ho (the "Reporting Person"). c/o IN8bio, Inc. Empire State Buildiing 350 5th Avenue, Suite 5330 New York, NY 10118 United States of America Y Row 9 of the Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of Common Stock beneficially owned by the Reporting Person and is incorporated by reference. Consists of (i) 85,112 shares of Common Stock held of record by the Reporting Person, (ii) 4,866 shares of Common Stock held of record by the Reporting Person's two minor children, (iii) 3,648 shares of Common Stock held of record by certain other relatives of the Reporting Person, over which, under all but certain limited circumstances, the Reporting Person holds an irrevocable proxy, pursuant to voting agreements between the Reporting Person, the Issuer, and such stockholders, (iv) 47,914 shares of Common Stock underlying outstanding options and 9,683 shares of Common Stock underlying warrants both held by the Reporting Person that are immediately exercisable or will be immediately exercisable within 60 days of June 30, 2025. Row 11 of the Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of Common Stock beneficially owned by the Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based on dividing (a) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 4,078,139 shares of Common Stock outstanding as of June 30, 2025 as reported by the Issuer on its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2025 and (ii) 47,914 shares of Common Stock underlying outstanding options and 9,683 shares of Common Stock underlying warrants both held by the Reporting Person that are immediately exercisable or will be immediately exercisable within 60 days of June 30, 2025. Row 5 of the Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to directthe vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 6 of the Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 7 of the Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 8 of the Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. N Y Y Y Y Y Y William Tai-Wei Ho /s/ William Tai-Wei Ho 08/13/2025